HIF1A and leukemia: ACF sensitizes drug-resistantcancer cells; therefore, its effectiveness has been proven in combinationtherapy with other drugs to which the body has already developed resistance.It was indicated that ACF constitutes the most potent HIF-1 inhibitorout of the 336 FDA-approved drugs.17 Currently,ACF has been shown to be effective against a broad spectrum of cancers(osteosarcoma, breast, brain, lung, liver, colon, ovarian, and pancreaticcancers, and leukemia).